Filing Details
- Accession Number:
- 0001179110-19-004062
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-03-19 17:25:06
- Reporting Period:
- 2019-03-15
- Accepted Time:
- 2019-03-19 17:25:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1597264 | Blueprint Medicines Corp | BPMC | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1638474 | W. Jeffrey Albers | C/O Blueprint Medicines Corporation 45 Sidney Street Cambridge MA 02139 | Ceo And President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-03-15 | 20,000 | $1.87 | 48,961 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-03-15 | 4,451 | $87.44 | 44,510 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-03-15 | 9,423 | $86.41 | 35,087 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-03-15 | 6,126 | $85.61 | 28,961 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-03-15 | 20,000 | $0.00 | 20,000 | $1.87 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 63,080 | 2024-07-30 | No | 4 | M | Direct |
Footnotes
- Effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.95 to $87.94 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.90 to $86.89 per share.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.02 to $85.89 per share.
- This option was granted on July 30, 2014. This option vests as follows: (i) 42,845 shares vested in four installments at a rate of 6,974 shares on September 21, 2016, and 11,957 shares on each of October 21, 2016 and November 21, 2016, and 11,957 on December 21, 2016; (ii) 90,010 shares vested in eight installments at a rate of 6,311 shares on May 21, 2017 and 11,957 shares on each of June 21, 2017, July 21, 2017, August 21, 2017, September 21, 2017, October 21, 2017, November 21, 2017 and December 21, 2017; and (iii) 30,225 shares vest in three installments at a rate of 6,311 shares on May 21, 2018, 11,957 shares on June 21, 2018 and 11,957 shares on July 21, 2018.
Billionaire Hedge Funds
